Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial

This prospective phase II study evaluated a regimen with vincristine, oral idarubicin and dexamethasone (VID) in 74 patients with multiple myeloma. A partial response was achieved in 57% (16/28) of patients with previously untreated disease and in 35% (16/46) with refractory diseases. VID chemothera...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica (Roma) 2004-03, Vol.89 (3), p.371-373
Main Authors: Glasmacher, A, Goldschmidt, H, Mezger, J, Haferlach, T, Schmidt-Wolf, IG, Gieseler, F, Phase II trial
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Dexamethasone - administration & dosage
Female
Humans
Idarubicin - administration & dosage
Male
Middle Aged
Multiple Myeloma - drug therapy
Prospective Studies
Vincristine - administration & dosage
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This prospective phase II study evaluated a regimen with vincristine, oral idarubicin and dexamethasone (VID) in 74 patients with multiple myeloma. A partial response was achieved in 57% (16/28) of patients with previously untreated disease and in 35% (16/46) with refractory diseases. VID chemotherapy is an effective and tolerable oral alternative in an outpatient setting for these patients.
ISSN:0390-6078
1592-8721